Influence of Treatment Intensification on A1c in Patients with Suboptimally Controlled Type 2 Diabetes After 2 Oral Antidiabetic Agents

Journal of Managed Care & Specialty Pharmacy
Kibum KimDiana Brixner

Abstract

In the United States, more than 50% of patients with type 2 diabetes mellitus (T2DM) have hemoglobin A1c (A1c) levels that fail to achieve the recommended target of < 7.0%. Of these, 30%-45% have an A1c > 9.0%, the threshold for poorly controlled T2DM per National Committee for Quality Assurance (NCQA) measures. Treatment inertia is a known challenge. However, recent treatment intensification patterns and outcomes after treatment fails 2 classes of oral antidiabetic agents (OADs) are not well understood. To characterize treatment intensification patterns and glycemic control outcomes in patients with A1c ≥ 7.0% on 2 OADs. A retrospective cohort study was conducted in patients with T2DM from a regional health plan claims dataset augmented with A1c results between January 1, 2010, and March 31, 2017. Patients were identified with an A1c ≥ 7.0% (baseline), while on 2 OADs, and whose treatment was intensified with basal/biphasic insulin (insulin), glucagon-like peptide-1 receptor antagonist (GLP-1RA), or a third OAD within 365 days after the baseline A1c ≥ 7.0%. Patients had at least 1 A1c value 60-365 days (follow-up period) after treatment intensification. The proportion of patients with an A1c < 7.0% and < 9.0% at follow-up were...Continue Reading

References

Nov 25, 2005·Pharmacotherapy·Kelly R RagucciElinor C Chumney
Dec 25, 2010·Pharmacotherapy·Lori M DickersonUNKNOWN National Interdisciplinary Primary Care Practice-Based Research Network
Dec 12, 2012·Journal of the American Pharmacists Association : JAPhA·Lourdes G PlanasDonald L Harrison
Mar 8, 2013·Diabetes Care·UNKNOWN American Diabetes Association
Apr 26, 2013·The New England Journal of Medicine·Mohammed K AliEdward W Gregg
May 29, 2013·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·M MonamiE Mannucci
May 11, 2016·Diabetes, Obesity & Metabolism·A Z Fu, J J Sheehan
Apr 19, 2017·Journal of Diabetes and Its Complications·William P GlasheenYanting Dong
Apr 25, 2017·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Philip A LevinSeoyoung C Kim
Dec 10, 2017·Diabetes Care·UNKNOWN American Diabetes Association
Dec 10, 2017·Diabetes Care·UNKNOWN American Diabetes Association
Jan 26, 2018·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Alan J GarberGuillermo E Umpierrez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.